Get the Stockscreener App
16.95
3.15%
-0.845
After Hours:
16.47
-0.475
-2.80%
Sensei Biotherapeutics Inc stock is traded at $16.95, with a volume of 26,257.
It is down -3.15% in the last 24 hours and down -45.80% over the past month.
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.
See More
Previous Close:
$17.79
Open:
$18.48
24h Volume:
26,257
Relative Volume:
0.32
Market Cap:
$22.48M
Revenue:
-
Net Income/Loss:
$-24.14M
P/E Ratio:
-1.2117
EPS:
-13.985
Net Cash Flow:
$-22.40M
1W Performance:
+2.74%
1M Performance:
-45.80%
6M Performance:
+103.91%
1Y Performance:
+191.54%
1-Day Range:
$16.75
$18.59
1-Week Range:
$16.43
$19.42
52-Week Range:
$5.31
$36.76
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
(240) 243-8000
Address
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
Compare SNSE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
16.75 | 23.87M | 0 | -24.14M | -22.40M | -13.98 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Leerink Partners | Outperform |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
| Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-01-21 | Initiated | Berenberg | Buy |
| Mar-01-21 | Initiated | Citigroup | Buy |
| Mar-01-21 | Initiated | Oppenheimer | Outperform |
| Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Sensei Biotherapeutics Inc. (SNSE) Q1 2026 Earnings: Deep EPS Miss Reflects Heavy R&D Investment and Pre-Revenue StatusDiluted EPS Report - Newser
SNSE Q1 2026 Earnings: EPS Significantly Below Estimates as Company Invests in PipelineCommunity Buy Signals - Newser
SNSE Initiated Coverage by Citigroup -- Rating Set to Buy with $55 Target - GuruFocus
Sensei Biotherapeutics Updates 2026 Board Reconstitution Plans - TipRanks
Sensei Biotherapeutics (SNSE) revises 2026 board reconstitution timeline - Stock Titan
Sensei Biotherapeutics (SNSE) Q1 2026 Earnings: Massive EPS Miss Overshadowed by Upbeat SentimentReal Trader Network - Newser
Sensei Biotherapeutics Acquires Faeth Therapeutics, Raises $200 Million and Issues Series B Preferred Stock Conversion to Common Shares 1 - Minichart
Sensei Biotherapeutics Sets Vote on Series B Conversion - TipRanks
Sensei Biotherapeutics to Convert Series B Preferred, Pro Forma Shows 25.7M Shares and $184.6M Equity - TradingView
$200M financing and Faeth deal reshape Sensei Biotherapeutics (NASDAQ: SNSE) - Stock Titan
SNSE SEC FilingsSensei Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
How Should Investors Value Sensei Biotherapeutics (SNSE) After Q - GuruFocus
Sensei Biotherapeutics Analyst Ratings and Price Targets | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - BioSpace
Sensei Biotherapeutics stock (US81728A1088): Q1 results and corporate update draw focus - AD HOC NEWS
Is Sensei Biotherapeutics (SNSE) Attractive After Q1 2026? EPS - GuruFocus
Millennium management reports $89k Sensei Biotherapeutics share sales - Investing.com
Millennium management reports $89k Sensei Biotherapeutics share sales By Investing.com - Investing.com South Africa
Millennium entities (SNSE) net sell 12,861 Sensei Biotherapeutics shares - Stock Titan
Sensei Biotherapeutics (SNSE) stake by Millennium entities hits 147,731 shares - Stock Titan
[Form 4] Sensei Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Millennium entities disclose 127,095 Sensei Biotherapeutics (SNSE) shares - Stock Titan
Sensei Biotherapeutics, Inc. Q1 2026 10-Q Filing: Financial Statements, Risk Factors, and Management Analysis - Minichart
Sensei Biotherapeutics (NASDAQ: SNSE) joint holders report 128,761 shares (9.6%) - Stock Titan
Transformative Quarter for Sensei Biotherapeutics (SNSE) - GuruFocus
Sensei Biotherapeutics Reports Q1 2026 Financial Results, Highlights PIKTOR Clinical Progress and Faeth Acquisition - Minichart
Sensei Biotherapeutics 1Q Research and Development Expenses $18.0M >SNSE - Moomoo
StemPoint (SNSE) and Michelle Ross report 9.9% stake in Sensei - Stock Titan
Sensei Biotherapeutics Releases Q1 2026 Financial Results - AlphaStreet
[SCHEDULE 13G] Sensei Biotherapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Sensei Biotherapeutics, Inc. 1Q 2026: Net income $(170.2M), EPS $(131.45) — 10-Q Summary - TradingView
SNSE: Faeth acquisition and $200M raise drive pipeline expansion; net loss rises on one-time costs - TradingView
Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position - TradingView
Sensei Biotherapeutics (SNSE) absorbs Faeth acquisition, $200M raise and going-concern risk - Stock Titan
Sensei Biotherapeutics (Nasdaq: SNSE) Q1 loss reflects Faeth acquisition impact - Stock Titan
Press Release: Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Sensei Biotherapeutics reports Q1 2026 loss on Faeth charges - grafa.com
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies - GlobeNewswire Inc.
TradingKey - TradingKey
Sensei Biotherapeutics Secures 200 Million Dollars for Oncology Pipeline - HarianBasis.co
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer - PharmiWeb.com
Sensei Biotherapeutics announces first patient dosed in FTH-PIK-101 trial - TipRanks
The competitive edge that makes Sensei Biotherapeutics (SNSE) special (-3.15%) 2026-05-05Most Discussed Stocks - newser.com
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer By Investing.com - Investing.com South Africa
Sensei Biotherapeutics begins trial of PIKTOR in breast cancer - Investing.com
10 Best Performing NASDAQ Stocks According to Wall Street Analysts - Insider Monkey
Short Selling Surges in Small-Cap Healthcare Stocks Amid Bearish Sentiment - GuruFocus
Sensei Biotherapeutics Inc expected to post a loss of 62 cents a shareEarnings Preview - TradingView
[144] Sensei Biotherapeutics, Inc. SEC Filing - Stock Titan
Sensei Biotherapeutics (SNSE) price target increased by 53.85% to 51.00 - MSN
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sensei Biotherapeutics Inc Stock (SNSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 07 '26 |
Buy |
33.38 |
1,108 |
36,985 |
133,986 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 06 '26 |
Buy |
31.02 |
1,104 |
34,246 |
141,029 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 07 '26 |
Sale |
31.01 |
8,151 |
252,775 |
133,986 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 02 '26 |
Sale |
32.12 |
7,666 |
246,239 |
144,974 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 06 '26 |
Sale |
31.06 |
1,259 |
39,100 |
141,029 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 01 '26 |
Buy |
34.49 |
6,175 |
212,979 |
147,731 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Mar 31 '26 |
Buy |
28.16 |
6,005 |
169,121 |
146,657 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Mar 31 '26 |
Sale |
25.49 |
1,591 |
40,553 |
146,657 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Apr 01 '26 |
Sale |
31.65 |
1,150 |
36,396 |
147,731 |
| MILLENNIUM MANAGEMENT LLC | 10% Owner |
Mar 27 '26 |
Buy |
26.61 |
15,321 |
407,717 |
142,360 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):